Cantor Fitzgerald Forecasts Gossamer Bio FY2025 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Stock analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for Gossamer Bio in a research note issued on Monday, May 19th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company will post earnings per share of ($0.71) for the year, down from their previous estimate of ($0.70). The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Other equities research analysts also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a research report on Tuesday, March 18th. The Goldman Sachs Group lifted their target price on Gossamer Bio from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, May 16th. Finally, Wedbush reissued an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, May 16th.

Gossamer Bio Trading Down 2.5%

Shares of NASDAQ:GOSS opened at $1.15 on Wednesday. The company has a market cap of $261.30 million, a P/E ratio of -3.59 and a beta of 1.82. The stock’s 50-day moving average is $1.03 and its 200-day moving average is $1.00. Gossamer Bio has a 52-week low of $0.50 and a 52-week high of $1.55. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business had revenue of $9.89 million during the quarter, compared to analyst estimates of $3.95 million.

Institutional Investors Weigh In On Gossamer Bio

Institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its position in Gossamer Bio by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock worth $1,123,000 after buying an additional 13,902 shares in the last quarter. Silverarc Capital Management LLC lifted its stake in Gossamer Bio by 9.3% during the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock worth $5,583,000 after purchasing an additional 526,495 shares during the period. Allostery Investments LP bought a new position in Gossamer Bio during the fourth quarter worth about $555,000. Alyeska Investment Group L.P. lifted its stake in Gossamer Bio by 52.7% during the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock worth $7,968,000 after purchasing an additional 3,041,058 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Gossamer Bio by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company’s stock worth $2,037,000 after purchasing an additional 38,084 shares during the period. 81.23% of the stock is owned by institutional investors and hedge funds.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.